Published in Cancer Weekly, December 23rd, 2008
"The antiserum derived from sTnNPhAc alpha or sTnNPhAc beta-KLH-inoculated mice was similarly reactive to sTnNPhAc alpha and sTnNPhAc but showed very little reactivity to sTn, NeuNPhAc alpha(2,3)GalNAc-a regioisomer of sTnNPhAc, isolated phenylacetyl group, and the linker employed to conjugate sTnNPhAc and carrier protein. It was concluded that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.